Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | RARA | P10276 | 1/20 | 0.55 |
| ▸ | RARB | P10826 | 1/20 | 0.55 |
| ▸ | RARG | P13631 | 1/20 | 0.55 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643489 | 1.00 | KDM4E (0.61) | KDM4EGAAPOLBHSD17B10TDP1 | |
| SCHEMBL3526351 | 0.98 | TTR (0.59) | KDM4EGAAPOLBHSD17B10TDP1 | |
| SCHEMBL2870314 | 0.92 | KDM4E (0.53) | KDM4EGAAPOLBHSD17B10TDP1 | |
| SCHEMBL3533360 | 0.85 | TTR (0.59) | KDM4EGAAPOLBHSD17B10TTR | |
| SCHEMBL20577940 | 0.85 | TTR (0.55) | KDM4EGAAPOLBHSD17B10TDP1 | |
| SCHEMBL28000110 | 0.85 | TTR (0.59) | KDM4EGAAPOLBHSD17B10TDP1 | |
| SCHEMBL580653 | 0.85 | TTR (0.55) | KDM4EGAAPOLBHSD17B10TDP1 | |
| SCHEMBL580818 | 0.85 | TTR (0.55) | KDM4EGAATTRTSHR | |
| SCHEMBL1397423 | 0.85 | ALDH1A1 (0.55) | KDM4EGAAHSD17B10L3MBTL1TAAR1 | |
| SCHEMBL17386600 | 0.85 | TAAR1 (0.56) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104478821-B | Oxadiazole diaryl compounds | 默克雪兰诺有限公司 | 2016-09-28 | — | — | CN | disclosed |
| EP-2354134-B1 | 2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR | ASTELLAS PHARMA INC (JP) | 2016-02-24 | — | — | EP | disclosed |
| CN-101815707-B | oxadiazole diaryl compounds | MERCK SERONO S.A. (CH) | 2015-09-02 | — | — | CN | disclosed |
| EP-2193126-B1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO SA (CH) | 2015-06-24 | — | — | EP | disclosed |
| EP-2193126-B1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO SA (CH) | 2015-06-24 | — | — | EP | disclosed |
| CN-104478821-A | Oxadiazole diaryl compounds | MERCK SERONO SA | 2015-04-01 | — | — | CN | disclosed |
| US-8889668-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2014-11-18 | — | — | US | disclosed |
| US-8889668-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2014-11-18 | — | — | US | disclosed |
| US-8889668-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20130109676-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA (CH) | 2013-05-02 | — | — | US | disclosed |
| EP-2193126-A1 | OXADIAZOLE DIARYL COMPOUNDS | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| US-7655669-B2 | Pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| WO-2009043890-A1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043890-A1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| CN-100404528-C | Novel pyrimidinamine derivatives and use thereof | NOVARTIS AG (CH) | 2008-07-23 | — | — | CN | disclosed |
| EP-1546127-B1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| CN-1684951-A | Novel pyrimidinamine derivatives and use thereof | NOVARTIS AG (CH) | 2005-10-19 | — | — | CN | disclosed |
| EP-1546127-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | Novartis AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029038-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | TYMP, NME2, DPYD | KDM4E 2764/4885GAA 1055/4885POLB 694/4885 |
| US-20130109676-A1 | Oxadiazole Diaryl Compounds | OXA1L, RO60, SSB | KDM4E 1265/4885GAA 4505/4885POLB 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.